Does the media refer more to TSHA or HHH?

In the previous week, Howard Hughes had 3 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 8 mentions for Howard Hughes and 5 mentions for Taysha Gene Therapies. Taysha Gene Therapies' average media sentiment score of 0.33 beat Howard Hughes' score of -0.14 indicating that Taysha Gene Therapies is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Taysha Gene Therapies 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Howard Hughes 1 Very Positive mention(s) 0 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media refer more to TSHA or KYMR?

In the previous week, Kymera Therapeutics had 1 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 6 mentions for Kymera Therapeutics and 5 mentions for Taysha Gene Therapies. Kymera Therapeutics' average media sentiment score of 1.18 beat Taysha Gene Therapies' score of 0.33 indicating that Kymera Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Taysha Gene Therapies 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Kymera Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media favor LNTH or TSHA?

In the previous week, Taysha Gene Therapies had 1 more articles in the media than Lantheus. MarketBeat recorded 5 mentions for Taysha Gene Therapies and 4 mentions for Lantheus. Lantheus' average media sentiment score of 0.54 beat Taysha Gene Therapies' score of 0.33 indicating that Lantheus is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Lantheus 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Taysha Gene Therapies 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer PTGX or TSHA?

In the previous week, Taysha Gene Therapies had 1 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 5 mentions for Taysha Gene Therapies and 4 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 0.64 beat Taysha Gene Therapies' score of 0.33 indicating that Protagonist Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Protagonist Therapeutics 2 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Taysha Gene Therapies 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is SYRE or TSHA more profitable?

Spyre Therapeutics' return on equity of -42.88% beat Taysha Gene Therapies' return on equity. Company Net Margins Return on Equity Return on Assets Spyre Therapeutics N/A -42.88% -27.76% Taysha Gene Therapies N/A -56.07% -40.16%

Does the media prefer SYRE or TSHA?

In the previous week, Spyre Therapeutics had 6 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 11 mentions for Spyre Therapeutics and 5 mentions for Taysha Gene Therapies. Taysha Gene Therapies' average media sentiment score of 0.33 beat Spyre Therapeutics' score of 0.01 indicating that Taysha Gene Therapies is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Spyre Therapeutics 3 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Taysha Gene Therapies 1 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Taysha Gene Therapies (TSHA) Competitors

$5.43 -0.07 (-1.27%)

Closing price 04:00 PM Eastern

Extended Trading

$5.53 +0.10 (+1.84%)

As of 05:20 PM Eastern

Compare

TSHA vs. HHH, KYMR, LNTH, PTGX, and SYRE

Should you buy Taysha Gene Therapies stock or one of its competitors? MarketBeat compares Taysha Gene Therapies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Taysha Gene Therapies include Howard Hughes (HHH), Kymera Therapeutics (KYMR), Lantheus (LNTH), Protagonist Therapeutics (PTGX), and Spyre Therapeutics (SYRE).

How does Taysha Gene Therapies compare to Howard Hughes?

Taysha Gene Therapies (NASDAQ:TSHA) and Howard Hughes (NYSE:HHH) are related companies, but which is the better stock? We will compare the two businesses based on the strength of their media sentiment, dividends, analyst recommendations, earnings, profitability, valuation, institutional ownership and risk.

Taysha Gene Therapies has a beta of 1.19, indicating that its share price is 19% more volatile than the broader market. Comparatively, Howard Hughes has a beta of 1.14, indicating that its share price is 14% more volatile than the broader market.

Howard Hughes has higher revenue and earnings than Taysha Gene Therapies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Howard Hughes, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Taysha Gene Therapies	$7.47M	208.86	-$109M	-$0.38	N/A
Howard Hughes	$1.51B	2.56	$131.88M	$2.04	31.82

In the previous week, Howard Hughes had 3 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 8 mentions for Howard Hughes and 5 mentions for Taysha Gene Therapies. Taysha Gene Therapies' average media sentiment score of 0.33 beat Howard Hughes' score of -0.14 indicating that Taysha Gene Therapies is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Taysha Gene Therapies	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Howard Hughes	1 Very Positive mention(s)	0 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Howard Hughes has a net margin of 8.04% compared to Taysha Gene Therapies' net margin of 0.00%. Howard Hughes' return on equity of 5.41% beat Taysha Gene Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Taysha Gene Therapies	N/A	-56.07%	-40.16%
Howard Hughes	8.04%	5.41%	1.61%

Taysha Gene Therapies presently has a consensus price target of $11.64, indicating a potential upside of 114.30%. Howard Hughes has a consensus price target of $85.00, indicating a potential upside of 30.95%. Given Taysha Gene Therapies' stronger consensus rating and higher probable upside, equities research analysts plainly believe Taysha Gene Therapies is more favorable than Howard Hughes.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Howard Hughes	2 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.33

77.7% of Taysha Gene Therapies shares are owned by institutional investors. Comparatively, 93.8% of Howard Hughes shares are owned by institutional investors. 3.8% of Taysha Gene Therapies shares are owned by company insiders. Comparatively, 48.0% of Howard Hughes shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Summary

Howard Hughes beats Taysha Gene Therapies on 10 of the 17 factors compared between the two stocks.

How does Taysha Gene Therapies compare to Kymera Therapeutics?

Taysha Gene Therapies (NASDAQ:TSHA) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, profitability, institutional ownership, media sentiment, earnings, dividends and analyst recommendations.

In the previous week, Kymera Therapeutics had 1 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 6 mentions for Kymera Therapeutics and 5 mentions for Taysha Gene Therapies. Kymera Therapeutics' average media sentiment score of 1.18 beat Taysha Gene Therapies' score of 0.33 indicating that Kymera Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Taysha Gene Therapies	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Kymera Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Taysha Gene Therapies has a net margin of 0.00% compared to Kymera Therapeutics' net margin of -611.94%. Kymera Therapeutics' return on equity of -24.71% beat Taysha Gene Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Taysha Gene Therapies	N/A	-56.07%	-40.16%
Kymera Therapeutics	-611.94%	-24.71%	-22.05%

Taysha Gene Therapies has higher earnings, but lower revenue than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Taysha Gene Therapies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Taysha Gene Therapies	$7.47M	208.86	-$109M	-$0.38	N/A
Kymera Therapeutics	$51.48M	118.17	-$311.35M	-$3.57	N/A

Taysha Gene Therapies presently has a consensus price target of $11.64, indicating a potential upside of 114.30%. Kymera Therapeutics has a consensus price target of $118.10, indicating a potential upside of 59.70%. Given Taysha Gene Therapies' stronger consensus rating and higher probable upside, equities analysts clearly believe Taysha Gene Therapies is more favorable than Kymera Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Kymera Therapeutics	1 Sell rating(s)	0 Hold rating(s)	21 Buy rating(s)	1 Strong Buy rating(s)	2.96

77.7% of Taysha Gene Therapies shares are owned by institutional investors. 3.8% of Taysha Gene Therapies shares are owned by company insiders. Comparatively, 16.0% of Kymera Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Taysha Gene Therapies has a beta of 1.19, suggesting that its stock price is 19% more volatile than the broader market. Comparatively, Kymera Therapeutics has a beta of 2.02, suggesting that its stock price is 102% more volatile than the broader market.

Summary

Taysha Gene Therapies beats Kymera Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Taysha Gene Therapies compare to Lantheus?

Lantheus (NASDAQ:LNTH) and Taysha Gene Therapies (NASDAQ:TSHA) are both medical companies, but which is the better business? We will contrast the two companies based on the strength of their dividends, valuation, analyst recommendations, media sentiment, institutional ownership, risk, profitability and earnings.

Lantheus has a beta of -0.03, indicating that its stock price is 103% less volatile than the broader market. Comparatively, Taysha Gene Therapies has a beta of 1.19, indicating that its stock price is 19% more volatile than the broader market.

Lantheus has higher revenue and earnings than Taysha Gene Therapies. Taysha Gene Therapies is trading at a lower price-to-earnings ratio than Lantheus, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantheus	$1.55B	4.21	$233.56M	$4.15	24.10
Taysha Gene Therapies	$7.47M	208.86	-$109M	-$0.38	N/A

In the previous week, Taysha Gene Therapies had 1 more articles in the media than Lantheus. MarketBeat recorded 5 mentions for Taysha Gene Therapies and 4 mentions for Lantheus. Lantheus' average media sentiment score of 0.54 beat Taysha Gene Therapies' score of 0.33 indicating that Lantheus is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lantheus	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Taysha Gene Therapies	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Lantheus has a net margin of 18.05% compared to Taysha Gene Therapies' net margin of 0.00%. Lantheus' return on equity of 29.32% beat Taysha Gene Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantheus	18.05%	29.32%	15.00%
Taysha Gene Therapies	N/A	-56.07%	-40.16%

99.1% of Lantheus shares are owned by institutional investors. Comparatively, 77.7% of Taysha Gene Therapies shares are owned by institutional investors. 1.7% of Lantheus shares are owned by insiders. Comparatively, 3.8% of Taysha Gene Therapies shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Lantheus currently has a consensus price target of $101.86, indicating a potential upside of 1.85%. Taysha Gene Therapies has a consensus price target of $11.64, indicating a potential upside of 114.30%. Given Taysha Gene Therapies' stronger consensus rating and higher probable upside, analysts clearly believe Taysha Gene Therapies is more favorable than Lantheus.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantheus	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Lantheus beats Taysha Gene Therapies on 9 of the 17 factors compared between the two stocks.

How does Taysha Gene Therapies compare to Protagonist Therapeutics?

Protagonist Therapeutics (NASDAQ:PTGX) and Taysha Gene Therapies (NASDAQ:TSHA) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, media sentiment, risk, earnings, valuation, institutional ownership and dividends.

Taysha Gene Therapies has lower revenue, but higher earnings than Protagonist Therapeutics. Protagonist Therapeutics is trading at a lower price-to-earnings ratio than Taysha Gene Therapies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Protagonist Therapeutics	$74.06M	85.12	-$130.15M	-$1.81	N/A
Taysha Gene Therapies	$7.47M	208.86	-$109M	-$0.38	N/A

Protagonist Therapeutics has a beta of 1.85, suggesting that its stock price is 85% more volatile than the broader market. Comparatively, Taysha Gene Therapies has a beta of 1.19, suggesting that its stock price is 19% more volatile than the broader market.

In the previous week, Taysha Gene Therapies had 1 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 5 mentions for Taysha Gene Therapies and 4 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 0.64 beat Taysha Gene Therapies' score of 0.33 indicating that Protagonist Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Protagonist Therapeutics	2 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Taysha Gene Therapies	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

98.6% of Protagonist Therapeutics shares are held by institutional investors. Comparatively, 77.7% of Taysha Gene Therapies shares are held by institutional investors. 5.2% of Protagonist Therapeutics shares are held by insiders. Comparatively, 3.8% of Taysha Gene Therapies shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Taysha Gene Therapies has a net margin of 0.00% compared to Protagonist Therapeutics' net margin of -154.88%. Protagonist Therapeutics' return on equity of -17.76% beat Taysha Gene Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Protagonist Therapeutics	-154.88%	-17.76%	-16.47%
Taysha Gene Therapies	N/A	-56.07%	-40.16%

Protagonist Therapeutics currently has a consensus price target of $115.21, indicating a potential upside of 17.53%. Taysha Gene Therapies has a consensus price target of $11.64, indicating a potential upside of 114.30%. Given Taysha Gene Therapies' stronger consensus rating and higher possible upside, analysts plainly believe Taysha Gene Therapies is more favorable than Protagonist Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Protagonist Therapeutics	1 Sell rating(s)	1 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.88
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

Summary

Taysha Gene Therapies beats Protagonist Therapeutics on 9 of the 17 factors compared between the two stocks.

How does Taysha Gene Therapies compare to Spyre Therapeutics?

Spyre Therapeutics (NASDAQ:SYRE) and Taysha Gene Therapies (NASDAQ:TSHA) are both medical companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, profitability, valuation, institutional ownership, risk, dividends, earnings and analyst recommendations.

Spyre Therapeutics' return on equity of -42.88% beat Taysha Gene Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Spyre Therapeutics	N/A	-42.88%	-27.76%
Taysha Gene Therapies	N/A	-56.07%	-40.16%

80.4% of Spyre Therapeutics shares are held by institutional investors. Comparatively, 77.7% of Taysha Gene Therapies shares are held by institutional investors. 15.7% of Spyre Therapeutics shares are held by company insiders. Comparatively, 3.8% of Taysha Gene Therapies shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Spyre Therapeutics currently has a consensus price target of $91.33, indicating a potential upside of 26.85%. Taysha Gene Therapies has a consensus price target of $11.64, indicating a potential upside of 114.30%. Given Taysha Gene Therapies' higher possible upside, analysts plainly believe Taysha Gene Therapies is more favorable than Spyre Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Spyre Therapeutics	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00
Taysha Gene Therapies	1 Sell rating(s)	0 Hold rating(s)	10 Buy rating(s)	2 Strong Buy rating(s)	3.00

In the previous week, Spyre Therapeutics had 6 more articles in the media than Taysha Gene Therapies. MarketBeat recorded 11 mentions for Spyre Therapeutics and 5 mentions for Taysha Gene Therapies. Taysha Gene Therapies' average media sentiment score of 0.33 beat Spyre Therapeutics' score of 0.01 indicating that Taysha Gene Therapies is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Spyre Therapeutics	3 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Taysha Gene Therapies	1 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Spyre Therapeutics has a beta of 3.05, meaning that its share price is 205% more volatile than the broader market. Comparatively, Taysha Gene Therapies has a beta of 1.19, meaning that its share price is 19% more volatile than the broader market.

Taysha Gene Therapies has higher revenue and earnings than Spyre Therapeutics. Spyre Therapeutics is trading at a lower price-to-earnings ratio than Taysha Gene Therapies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Spyre Therapeutics	N/A	N/A	-$155.20M	-$2.08	N/A
Taysha Gene Therapies	$7.47M	208.86	-$109M	-$0.38	N/A

Summary

Spyre Therapeutics and Taysha Gene Therapies tied by winning 6 of the 12 factors compared between the two stocks.

Get Taysha Gene Therapies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding TSHA and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

TSHA vs. The Competition

Export

Metric	Taysha Gene Therapies	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.56B	$5.76B	$6.43B	$12.06B
Dividend Yield	N/A	0.69%	2.67%	5.56%
P/E Ratio	-14.29	8.49	23.77	23.75
Price / Sales	208.86	25.20	479.87	84.46
Price / Cash	N/A	8.41	26.99	37.25
Price / Book	6.03	4.12	10.33	6.80
Net Income	-$109M	$99.67M	$3.57B	$337.51M
7 Day Performance	-9.05%	-1.92%	-1.43%	-2.59%
1 Month Performance	-20.26%	0.68%	3.33%	2.02%
1 Year Performance	91.20%	129.53%	23.49%	26.63%

Taysha Gene Therapies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
TSHA Taysha Gene Therapies	3.5438 of 5 stars	$5.43 -1.3%	$11.64 +114.3%	+93.7%	$1.56B	$7.47M	N/A	180
HHH Howard Hughes	3.2413 of 5 stars	$62.80 -0.9%	$85.00 +35.3%	-5.3%	$3.78B	$1.51B	30.78	608	News Coverage
KYMR Kymera Therapeutics	2.4828 of 5 stars	$78.47 -3.6%	$118.10 +50.5%	+55.7%	$6.70B	$39.21M	N/A	170	News Coverage Analyst Forecast
LNTH Lantheus	2.1715 of 5 stars	$97.13 -2.2%	$101.86 +4.9%	+23.8%	$6.47B	$1.55B	23.40	1,193
PTGX Protagonist Therapeutics	2.4663 of 5 stars	$94.92 -4.7%	$115.21 +21.4%	+79.1%	$6.40B	$74.06M	N/A	120

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:TSHA) was last updated on 6/8/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Taysha Gene Therapies (TSHA) Competitors

TSHA vs. HHH, KYMR, LNTH, PTGX, and SYRE

How does Taysha Gene Therapies compare to Howard Hughes?

Summary

How does Taysha Gene Therapies compare to Kymera Therapeutics?

Summary

How does Taysha Gene Therapies compare to Lantheus?

Summary

How does Taysha Gene Therapies compare to Protagonist Therapeutics?

Summary

How does Taysha Gene Therapies compare to Spyre Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TSHA vs. The Competition

Taysha Gene Therapies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Taysha Gene Therapies (TSHA) Competitors

TSHA vs. HHH, KYMR, LNTH, PTGX, and SYRE

How does Taysha Gene Therapies compare to Howard Hughes?

Which has more volatility & risk, TSHA or HHH?

Which has preferable earnings & valuation, TSHA or HHH?

Does the media refer more to TSHA or HHH?

Is TSHA or HHH more profitable?

Do analysts prefer TSHA or HHH?

Do institutionals & insiders believe in TSHA or HHH?

Summary

How does Taysha Gene Therapies compare to Kymera Therapeutics?

Does the media refer more to TSHA or KYMR?

Is TSHA or KYMR more profitable?

Which has higher earnings and valuation, TSHA or KYMR?

Do analysts recommend TSHA or KYMR?

Do institutionals and insiders believe in TSHA or KYMR?

Which has more volatility & risk, TSHA or KYMR?

Summary

How does Taysha Gene Therapies compare to Lantheus?

Which has more risk & volatility, LNTH or TSHA?

Which has higher valuation & earnings, LNTH or TSHA?

Does the media favor LNTH or TSHA?

Is LNTH or TSHA more profitable?

Do insiders & institutionals believe in LNTH or TSHA?

Do analysts recommend LNTH or TSHA?

Summary

How does Taysha Gene Therapies compare to Protagonist Therapeutics?

Which has stronger valuation & earnings, PTGX or TSHA?

Which has more risk & volatility, PTGX or TSHA?

Does the media prefer PTGX or TSHA?

Do institutionals & insiders believe in PTGX or TSHA?

Is PTGX or TSHA more profitable?

Do analysts rate PTGX or TSHA?

Summary

How does Taysha Gene Therapies compare to Spyre Therapeutics?

Is SYRE or TSHA more profitable?

Do institutionals and insiders believe in SYRE or TSHA?

Do analysts prefer SYRE or TSHA?

Does the media prefer SYRE or TSHA?

Which has more risk & volatility, SYRE or TSHA?

Which has stronger earnings & valuation, SYRE or TSHA?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

TSHA vs. The Competition

Taysha Gene Therapies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools